T3	No-of-participants 491 497	27,347
T4	eligibility 498 518	postmenopausal women
T5	average-age 524 538	50 to 79 years
T6	duration 570 587	from 1993 to 1998
T7	No-of-participants 664 670	16,608
T8	control 829 836	placebo
T9	No-of-participants 891 897	10,739
T10	duration 1044 1053	7.2 years
T11	outcome 1995 2022	invasive breast cancer risk
T12	outcome 1831 1849	breast cancer risk
T13	outcome 1631 1654	breast cancer incidence
T14	outcome 1306 1319	breast cancer
T1	intervention 27 35	Estrogen
T2	intervention 41 50	Progestin
